Oscar Tahuahua, Medical Oncology fellow at the National Cancer Institute of Mexico, shared on X about a recent paper by Andrea Cercek et al. published in NEJM:
“Nonoperative Management of Mismatch Repair–Deficient Tumors in NEJM
Ph 2 study, neoadjuvant dostarlimab (PD-1 inh) achieved 82% cCR and 80% organ preservation in stage I–III dMMR tumors, with 92% 2-year RFS; 44% had Lynch syndrome”
Authors: Andrea Cercek, Michael B. Foote, Benoit Rousseau, J. Joshua Smith, Jinru Shia, Jenna Sinopoli, Jill Weiss, Melissa Lumish, Lindsay Temple, Miteshkumar Patel, Callahan Wilde, Leonard B. Saltz, Guillem Argiles, Zsofia Stadler, Oliver Artz, Steven Maron, Geoffrey Ku, Ping Gu, Yelena Y. Janjigian, Daniela Molena, Gopa Iyer, Jonathan Coleman, Wassim Abida, Seth Cohen, Kevin Soares, Mark Schattner, Vivian E. Strong, Rona Yaeger, Philip Paty, Marina Shcherba, Ryan Sugarman, Paul B. Romesser, Alice Zervoudakis, Avni Desai, Neil H. Segal, Imane El Dika, Maria Widmar, Iris Wei, Emmanouil Pappou, Gerard Fumo, Santiago Aparo, Mithat Gonen, Marc Gollub, Vetri S. Jayaprakasham, Tae-Hyung Kim, Julio Garcia Aguilar, Martin Weiser, Luis A. Diaz, Jr.
Journal: NEJM – The New England Journal of Medicine
Read full insight here.
Read more about dMMR on OncoDaily:
“Organ Preservation in dMMR Tumors: Results from Neoadjuvant Phase II Study with Dostarlimab”
